We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Hematology Analyzers Offer Channel for Immature Platelet Fraction

By LabMedica International staff writers
Posted on 18 Jul 2012
AACC 2012: A hematology analyzer includes a fluorescent platelet channel for Immature Platelet Fraction (IPF), which will aid in the differential diagnosis of thrombocytopenia. More...
The scalable, series-wide compact design delivers a smaller footprint that improves workflow and transforms productivity.

The analyzers are among products from Sysmex's hematology, urinalysis, cell image analysis, and middleware portfolio that are on show at the annual AACC/AACLS conference Expo being held July 15-19, 2012, in Los Angeles, (CA, USA).

The Sysmex (Mundelein, IL, USA) XN-Series Hematology Analyzers enable laboratories of any size to implement advanced clinical parameters. The scalable, series-wide compact design delivers a smaller footprint that optimizes workflow and transforms productivity. The instruments are built on the concept of Silent Design, a fusion of product design and technology.

Expo in-booth educational presentations will feature topics about hematology technology, diabetes management, and advanced clinical parameters, among others. Sysmex manufactures clinical laboratory solutions, including clinical diagnostics, automation, and information systems, and services hospitals and healthcare networks, reference laboratories, and physicians' offices worldwide.

The Sysmex XN-Series Hematology Analyzer has been designed to enable clinical laboratories to withstand future medical technologist shortages; and the ability to keep up with workload demands and testing complexity that may accompany an aging population. "The human-centered approach of Silent Design, upon which the Sysmex XN-Series hematology analyzers are built, provides a simplified system of operation and interface based on careful study of laboratory processes, the relationship between the operator and the instrument, and how people work," said Ralph Taylor, executive vice president, marketing, business development, and medical affairs, Sysmex America, Inc.

Related Links:

Sysmex America




New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Online QC Software
Acusera 24•7
New
Prefilled Tubes
Prefilled 5.0ml Tubes
New
Total Laboratory Automation Solution
SATLARS Mini T8
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The findings point to the feasibility of a quick, noninvasive urine-based approach to support earlier decision-making in multiple psychiatric conditions (photo credit: Shutterstock)

Noninvasive Urine Test May Support Earlier Diagnosis of Psychiatric Disorders

Delays in diagnosing serious psychiatric conditions can leave patients without timely support and complicate treatment planning. For bipolar disorder, average time to diagnosis can exceed nine years, and... Read more

Molecular Diagnostics

view channel
Image: The schematic diagram links key MASLD, MASH, and MASLD-HCC molecular drivers to emerging multi‑omics biomarkers and therapeutic modalities, highlighting the current barriers in clinical translation and strategic solutions aimed at refined risk stratification and personalized medicine (Photo courtesy of ©Science China Press)

Emerging Biomarkers Advance Early Detection of MASLD and Liver Cancer Risk

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects about 30% of people worldwide and can advance to metabolic dysfunction-associated steatohepatitis (MASH), fibrosis, cirrhosis, and... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.